DOV, Merck Partner In $455M Deal Focused On Depression Aug. 9, 2004 By Karen Carey DOV Pharmaceutical Inc. licensed worldwide rights of its triple uptake inhibitor compounds for psychiatric disorders to Merck & Co. Inc. in a deal worth $455 million, if all milestones are met. (BioWorld Today)Read More
